StreetInsider.com News Articles

Roivant Sciences (ROIV) PT Raised to $47 at H.C. Wainwright

Wed, 09 Sep 2026 07:26:00 -0400

(Updated - September 9, 2026 7:26 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $47.00 (from $41.00) while maintaining a Buy rating.

The analyst commented: "Mosliciguat’s PHocus results strengthen Roivant’s third growth pillar; price target to $47, with potential for more upside, as Roivant puts up another impressive clinical win. Mosli delivered a 56.3% placebo-adjusted PVR reduction which is the largest reported in a randomized pulmonary-hypertension trial and a 35.2-meter 6MWD benefit at Week 16 that increased to 52.7 meters at Week 24. Recall, Tyvaso delivered a 31.1-meter benefit at Week 16 in

Roivant Sciences (ROIV) PT Raised to $47 at H.C. Wainwright

Wed, 09 Sep 2026 07:26:00 -0400

(Updated - September 9, 2026 7:26 AM EDT)

H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $47.00 (from $41.00) while maintaining a Buy rating.

Roivant Sciences (ROIV) PT Raised to $46 at Guggenheim

Wed, 09 Sep 2026 05:39:57 -0400

Guggenheim analyst Yastin Suneja raised the price target on Roivant Sciences (NASDAQ: ROIV) to $46.00 (from $42.00) while maintaining a Buy rating.

The analyst comments "Key Message: Phase II PHocus (n=135) tested mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, in PH-ILD and delivered PVR reduction well above Street expectations (56.3% placebo-adjusted vs. ~20–30% anticipated), with supportive benefit across 6MWD, NT-proBNP, and cough. With once-daily, single-inhalation dosing in a disease carrying median survival of just 1.5–2 years, mosliciguat is positioned as a potential first-in-class inhaled therapy for PH-ILD — as monotherapy or add-on — addressing the gap left by treprostinil and

Roivant Sciences (ROIV) PT Raised to $46 at Guggenheim

Wed, 09 Sep 2026 05:39:57 -0400

Guggenheim analyst Yastin Suneja raised the price target on Roivant Sciences (NASDAQ: ROIV) to $46.00 (from $42.00) while maintaining a Buy rating.

Roivant Sciences (ROIV) PT Raised to $55 at TD Cowen

Wed, 09 Sep 2026 05:38:27 -0400

TD Cowen analyst Yaron Werber raised the price target on Roivant Sciences (NASDAQ: ROIV) to $55.00 (from $50.00) while maintaining a Buy rating.

The analyst ocmments "Mosli delivers standout Ph2 PHocus readout in PH-ILD w/56% pbo-adj PVR reduction and +35.2m 6MWD at wk 16, both stat sig. This far exceeded physician/investor expectations on PVR (~32%) and 6MWD (20-32m). Lower cough burden, QD dosing, and Ph3 initiation strengthen its potential as mono/combo therapy. We now add mosli to our model w/peak sales of $1.6B (65% POS) in FY35. New PT $55 (+$5)."

Roivant Sciences (ROIV) PT Raised to $55 at TD Cowen

Wed, 09 Sep 2026 05:38:27 -0400

TD Cowen analyst Yaron Werber raised the price target on Roivant Sciences (NASDAQ: ROIV) to $55.00 (from $50.00) while maintaining a Buy rating.

Roivant Sciences (ROIV) PT Raised to $52 at Jefferies

Tue, 08 Sep 2026 10:53:07 -0400

Jefferies analyst Dennis Ding raised the price target on Roivant Sciences (NASDAQ: ROIV) to $52.00 (from $42.00) while maintaining a Buy rating.

The analyst comments "Big Picture: ROIV has been our top pick this year on clinical derisking across multiple programs, driving upside to peak sales estimates with each (+) catalyst. PH-ILD was mostly a call option given focus on brepo i.e. Rinvoq indication stacking playbook, the brepo DM launch, and also IMVT D2TRA update in H2, but today's PH-ILD data should finally drive more value in the stock to more appropriately incorporate a $3B+ peak sales pot'l in the stock.

Roivant Sciences (ROIV) PT Raised to $52 at Jefferies

Tue, 08 Sep 2026 10:53:07 -0400

Jefferies analyst Dennis Ding raised the price target on Roivant Sciences (NASDAQ: ROIV) to $52.00 (from $42.00) while maintaining a Buy rating.

Roivant Sciences (ROIV) PT Raised to $55 at Piper Sandler

Tue, 08 Sep 2026 09:47:43 -0400

Piper Sandler analyst Yasmeen Rahimi raised the price target on Roivant Sciences (NASDAQ: ROIV) to $55.00 (from $40.00) while maintaining a Overweight rating.

Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial

Tue, 08 Sep 2026 06:01:04 -0400

Roivant Sciences (Nasdaq: ROIV) announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a company statement. The results were presented at the European Respiratory Society International Congress 2026.

The trial met its primary endpoint, showing a placebo-adjusted reduction in pulmonary vascular resistance (PVR) of 56.3% at Week 16 (p<0.0001). The study enrolled 135 patients across 87 sites in 20 countries in a randomized, double-blind, placebo-controlled design.

The study also met its secondary endpoints at Week 16, with a placebo-adjusted improvement in six-minute walk distance (6MWD) of

Pulmovant's mosliciguat hits primary endpoint in PH-ILD phase 2 trial

Tue, 08 Sep 2026 06:00:51 -0400

Pulmovant, a subsidiary of Roivant Sciences (NASDAQ: ROIV), announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a company press release. The results were presented at the European Respiratory Society International Congress 2026.

The trial met its primary endpoint, showing a placebo-adjusted reduction in pulmonary vascular resistance (PVR) of 56.3% at Week 16 (p<0.0001). The study also met secondary endpoints, with a placebo-adjusted improvement in six-minute walk distance (6MWD) of 35.2 meters (p=0.0027) and a placebo-adjusted reduction in NT-proBNP, a cardiac strain biomarker, of 53.2%

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier S

Tue, 08 Sep 2026 06:00:00 -0400

PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial
The study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP, p=0.0002), both clinically meaningful and statistically significant
Pre-specificed exploratory Week 24 results showed continued placebo-adjusted improvements in 6MWD to +52.7m (nominal p<0.0001) and

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier S

Tue, 08 Sep 2026 06:00:00 -0400

PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial
The study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP, p=0.0002), both clinically meaningful and statistically significant
Pre-specificed exploratory Week 24 results showed continued placebo-adjusted improvements in 6MWD to +52.7m (nominal p<0.0001) and

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu

Tue, 08 Sep 2026 06:00:00 -0400

PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial
The study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP, p=0.0002), both clinically meaningful and statistically significant
Pre-specified exploratory Week 24 results showed continued placebo-adjusted improvements in 6MWD to +52.7m (nominal p<0.0001) and NT-proBNP to -75.9% (-487.1

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu

Tue, 08 Sep 2026 06:00:00 -0400

PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial
The study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP, p=0.0002), both clinically meaningful and statistically significant
Pre-specified exploratory Week 24 results showed continued placebo-adjusted improvements in 6MWD to +52.7m (nominal p<0.0001) and NT-proBNP to -75.9% (-487.1

Pulmovant to present Phase 2 mosliciguat results at ERS Congress

Sun, 06 Sep 2026 01:00:16 -0400

Pulmovant, a subsidiary of Roivant Sciences (NASDAQ: ROIV), announced that topline results from its Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society International Congress 2026 on September 8, 2026, at 12:15 CEST.

The presentation will be delivered by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.

The PHocus study (NCT06635850) is a randomized, double-blind, placebo-controlled global trial that enrolled 135 adult participants with PH-ILD to assess the safety and efficacy of

Roivant to present Phase 2 mosliciguat data at ERS Congress Sept. 8

Sun, 06 Sep 2026 01:00:12 -0400

Roivant Sciences (Nasdaq: ROIV) and its subsidiary Pulmovant announced that topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society International Congress 2026 on September 8, 2026.

The presentation is scheduled for 12:15 CEST (6:15 a.m. ET) and will be delivered by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.

Roivant will also host an investor call and webcast at 8:00 a.m. ET on the same day. An archived

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on

Sun, 06 Sep 2026 01:00:00 -0400

WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on

Sun, 06 Sep 2026 01:00:00 -0400

WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T

Sun, 06 Sep 2026 01:00:00 -0400

BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T

Sun, 06 Sep 2026 01:00:00 -0400

BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00

Form 144 Roivant Sciences Ltd. Filed by: Venker Eric

Fri, 28 Aug 2026 16:33:00 -0400
si-local-file:///var/storage/secattach/20260828/26998553.html

Form 144 Roivant Sciences Ltd. Filed by: Venker Eric

Fri, 28 Aug 2026 16:33:00 -0400
si-local-file:///var/storage/secattach/20260828/26998553.html

Form 8-K Roivant Sciences Ltd. For: Aug 28

Fri, 28 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260828/26998529.html

Form 8-K Roivant Sciences Ltd. For: Aug 28

Fri, 28 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260828/26998529.html